Germany, July 29 -- Germany based Gilead Sciences GmbH has secured contract from AOK PLUS - Die Gesundheitskasse fur Sachsen und Thuringen for Pharmaceutical products - Agreement according to Section 130c Paragraph 1 SGB V for the drug Epclusa with the active ingredient combination sofosbuvir/velpatasvir . The value of the contract is not disclosed .
Published by HT Digital Content Services with permission from Pivotal Sources....